New phase 3 data found that Johnson & Johnson’s (JNJ) Tecvayli (teclistamab) as monotherapy led to better progression-free and overall survival in multiple myeloma patients as a second-line therapy compared to standard of care.
The trial enrolled mostly patients who had failed on anti-CD38 therapy and Revlimid (lenalidomide).
Results showed that those on Tecvayli had a 71% reduction in the risk of disease progression or death and a 40% reduction in the risk of death compared to taking an anti-CD38 and Revlimid.
In December, J&J released the results of another phase 3 study demonstrating the benefit of Tecvayli plus Darzelex Faspro (daratumumab and hyaluronidase) in second-line multiple myeloma.
Tecvayli was approved in 2022 under accelerated approval for multiple myeloma after failing at least four prior therapies.
